ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025
Contrast-enhanced ultrasound for diagnosing subtypes of intrahepatic cholangiocarcinoma: a comparative study with poorly differentiated hepatocellular carcinoma.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Determinants and survival benefits of achieving textbook outcome for intrahepatic cholangiocarcinoma in the era of neoadjuvant therapy.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPathologically, intrahepatic cholangiocarcinoma (ICC) is classified into small-duct (SD) type and large-duct (LD) type, each with distinct clinicopathological characteristics. The contrast-enhanced ultrasound (CEUS) features of the two ICC types remain insufficiently explored. PURPOSE: To evaluate liver CEUS imaging for differentiating the SD and LD types of ICC and further compare them with poorly differentiated hepatocellular carcinoma (pHCC). MATERIALS AND
methodsA single-center retrospective study enrolled 252 patients with SD-type ICC, LD-type ICC, or pHCC between October 2017 and August 2023. Logistic regression analyses identified independent clinical, pathological, ultrasound, and CEUS predictors. Based on these features, a decision tree-based diagnostic model was developed. The model's performance was evaluated using receiver operating characteristic (ROC) curve analysis in both the training and validation cohorts, as well as in subgroup stratified by tumor size ≤ 5 cm and > 5 cm. Differences in overall survival (OS) and recurrence-free survival (RFS) based on the model were further analyzed.
resultsOverall, 252 patients (mean age, 58.4 ± 10.7 years; 174 males) with 140 SD-type ICC, 55 LD-type ICC and 57 pHCC were enrolled. Multivariate analysis revealed that AFP, CEA, CA19-9, HBsAg status, arterial phase enhancement pattern, washout time ≤ 45 s, and marked washout were independent predictors for tumor categories differentiation (all P <.05). The decision tree-based model incorporating the major features demonstrated excellent performance in both the training cohort (AUC 0.89) and validation cohort (AUC 0.88), as well as in tumor size ≤ 5 cm (AUC 0.90) and > 5 cm (AUC 0.84). OS was significantly worse in LD-type ICC patients compared to SD-type and pHCC (P <.05 for both), while RFS showed no significant difference.
conclusionsA user-friendly, decision tree-based diagnostic model was developed to accurately predict ICC subtypes and pHCC, facilitating improved clinical decision-making. The decision tree-based diagnostic model effectively diagnosed small-duct type and large-duct type intrahepatic cholangiocarcinoma, as well as poorly differentiated hepatocellular carcinoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.